...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Clovis' Rubracra

I agree that “late to the party” does not likely apply regarding PARP inhibitors, Don included PARP inhibitors in the list of drug classes that ZEN 3694 works synergistically with. I believe it was within the first 10 slides when he mentions the synergistic list. 

Share
New Message
Please login to post a reply